ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0936

Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial

Jin Kyun Park1, Yun Jong Lee2, Kichul Shin3, Eun Ha Kang2, You-Jung Ha2, Min Jung Kim4, Jun Won Park5, SE RIM CHOI5, Mi Hyeon Kim5, Ji In Jung5, Ju Yeon Kim5, Kevin Winthrop6 and Eun Bong Lee5, 1Seoul National University College of Medicine, Jongno-gu, Seoul, South Korea, 2Seoul National University Bundang Hospital, Seongnam, Republic of Korea, 3Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, 4Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, 5Seoul National University Hospital, Seoul, Republic of Korea, 6Oregon Health & Science University, Portland, OR

Meeting: ACR Convergence 2022

Keywords: clinical trial, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Methotrexate (MTX) significantly decreases the vaccine response to pneumococcal and seasonal influenza vaccines and temporarily discontinuing MTX for 2 weeks in patients with rheumatoid arthritis (RA) on a stable dose of MTX significantly increased immunogenicity. This study aimed to determine whether discontinuing methotrexate (MTX) for 1 week after seasonal influenza vaccination is non-inferior to discontinuing for 2 weeks in RA patients with regards to immediate and long-term vaccine response.

Methods: In this prospective randomized parallel-group multi-center non-inferiority trial study, RA patients on a stable dose of MTX were randomly assigned at a ratio of 1:1 to hold MTX for 1 week or 2 weeks after receiving the quadrivalent 2021–2022 seasonal influenza vaccine containing H1N1, H3N2, B-Yamagata, and B-Victoria strains. The primary outcome was the proportion of patients with a satisfactory vaccine response, which was defined as ≥4-fold increase in hemagglutination inhibition antibody titers against two or more of the four vaccine strains 4 weeks after vaccination. Secondary outcomes include positive response and antibody titers at 4 and 16 weeks after vaccination. Controls without autoimmune disease were included as a reference.

Results: The modified intention-to-treat population included 90 patients in the 1 week MTX hold group and 88 patients in the 2 week MTX hold group. The proportion of satisfactory vaccine responses did not differ between the groups at 4 weeks (68.9% vs. 75.0%, p = 0.364) and at 16 weeks (69.6% vs. 70.3%, p=0.915). The proportion of patients reaching seroprotection and the rise in antibody titer were similar between the groups at 4 and 16 weeks. Vaccine responses in RA patients and controls were similar.

Conclusion: Temporarily discontinuing MTX for 1 week is non-inferior to MTX discontinuation for 2 weeks after vaccination to induce an immediate and long-term satisfactory vaccine response to a seasonal influenza vaccine in patients with RA on a stable dose of MTX.

Supporting image 1

Figure. Study design and vaccine response at 4 and 16 weeks
(A) Study design. (B) The percentage of patients achieving a satisfactory vaccine response, defined as ≥4-fold increase in hemagglutination inhibition (HI) antibody titer 4 weeks and 16 weeks after vaccination against one or more, two or more , three or more, and four vaccine strains. The error bars represent the 95% confidence interval. The 1 week and 2 week MTX hold groups were compared by a chi-square test. The groups did not differ in regard to vaccine response (p >0.05).


Disclosures: J. Park, None; Y. Lee, None; K. Shin, None; E. Kang, None; Y. Ha, None; M. Kim, None; J. Park, None; S. CHOI, None; M. Kim, None; J. Jung, None; J. Kim, None; K. Winthrop, AbbVie, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Pfizer, Roche, Regeneron, Sanofi, UCB, AstraZeneca, Novartis; E. Lee, None.

To cite this abstract in AMA style:

Park J, Lee Y, Shin K, Kang E, Ha Y, Kim M, Park J, CHOI S, Kim M, Jung J, Kim J, Winthrop K, Lee E. Immediate and Long-term Effects of the MTX Discontinuation for 1 vs. 2 Weeks on Vaccine Response to Seasonal Influenza Vaccine: A Non-inferiority Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/immediate-and-long-term-effects-of-the-mtx-discontinuation-for-1-vs-2-weeks-on-vaccine-response-to-seasonal-influenza-vaccine-a-non-inferiority-randomized-controlled-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immediate-and-long-term-effects-of-the-mtx-discontinuation-for-1-vs-2-weeks-on-vaccine-response-to-seasonal-influenza-vaccine-a-non-inferiority-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology